MIR20A is a type of microRNA that is involved in mediating MYC and STAT3 dosage compensation through a redundant mechanism [PMC8627999]. In a study investigating regenerative therapy for jawbone atrophy, an atelocollagen-based gene-activated matrix (GAM) containing naked-pDNAs encoding MIR20A was used [PMC7955717]. The expression of MIR20A, along with other microRNAs, was assessed using RT-PCR and shown in Figure 4 [PMC9687337]. SNHG5, an upregulated gene, was found to reduce MIR20A expression and increase the expression of apoptosis proteins BECN1, ATG5, and ATG7 [PMC6912041]. Additionally, SNHG5 could interact with MIR32 to reduce the migration and proliferation effects of SNHG5 on gastric cancer cells [PMC6912041]. In a preliminary experiment using cultured MSCs, it was found that the delivery of MIR20A using an atelocollagen-based GAM had high transfection efficacy without cytotoxicity compared to commercial vectors such as a lentiviral vector [PMC7955717].
c -A G uguu guag acU AAGUGCUUAUAGUGCAG UAG u |||| ||| ||||||||||||||||| ||| a cguc uGA UUCACGAGUAUUACGUC Auc g a AA - uauu
Name | Accession | Chromosome | Start | End | Strand | Confidence |
---|
Disease | Description | Category | PubMed ID |
---|
Accession | MIMAT0000075 |
Description | Homo sapiens hsa-miR-20a-5p mature miRNA |
Sequence | 8 - UAAAGUGCUUAUAGUGCAGGUAG - 30 |
Evidence |
experimental
cloned [1,4-7], Northern [1] |
Database links | |
Predicted targets |
Accession | MIMAT0004493 |
Description | Homo sapiens hsa-miR-20a-3p mature miRNA |
Sequence | 44 - ACUGCAUUAUGAGCACUUAAAG - 65 |
Evidence |
experimental
cloned [6] |
Database links | |
Predicted targets |
|